Literature DB >> 18993155

Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.

Amandeep Singh Dhaliwal1, Audrius Bredikis, Gabriel Habib, Blase Anthony Carabello, Kumudha Ramasubbu, Biykem Bozkurt.   

Abstract

Previous trials have shown that digoxin was beneficial in patients with heart failure (HF). However, these studies were conducted before the incorporation of beta blockers as standard therapy for patients with HF. The purpose of this study was to determine the effect of digoxin in patients with HF on a contemporary regimen of renin-angiotensin inhibition and beta blockade. In 347 almost exclusively men, data pertaining to the index hospitalization and occurrence of all-cause mortality or readmission for HF were collected. Cox proportional hazard modeling was used. Patients on digoxin therapy had a lower left ventricular (LV) ejection fraction (EF), higher prevalence of previous hospitalizations for HF and atrial fibrillation, and lower prevalence of hypertension. After adjustment for age, LVEF, history of HF hospitalizations, New York Heart Association class, presence of chronic renal insufficiency, presence of atrial fibrillation, and prescriptions for beta blockers and angiotensin converting enzyme inhibitors or angiotensin receptor blockers, HF hospitalizations (hazard ratio 1.08, 95% confidence interval [CI] 0.77 to 1.50, p = 0.66), total mortality (hazard ratio 1.03, 95% CI 0.78 to 1.35, p = 0.85), or the combined end point of HF hospitalization and total mortality (hazard ratio 1.11, 95% CI 0.81 to 1.53, p = 0.52) were not different in patients using digoxin compared with those not using digoxin. Clinical outcomes were not different in subgroups of patients with EF < or =25%, New York Heart Association class III or IV, atrial fibrillation, heart rate < or =60 beats/min, or patients on beta-blocker therapy. In conclusion, digoxin use was not associated with a decrease in HF hospitalizations or overall mortality rates in a cohort of hospitalized patients with HF with LV systolic dysfunction on contemporary background HF treatment including angiotensin-converting enzyme inhibitors and beta blockers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18993155     DOI: 10.1016/j.amjcard.2008.07.014

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Digoxin treatment in heart failure--unveiling risk by cluster analysis of DIG data.

Authors:  Sameer Ather; Leif E Peterson; Vijay G Divakaran; Anita Deswal; Kumudha Ramasubbu; Irakli Giorgberidze; Alvin Blaustein; Xander H T Wehrens; Douglas L Mann; Biykem Bozkurt
Journal:  Int J Cardiol       Date:  2010-05-15       Impact factor: 4.164

Review 2.  Digitalis for treatment of heart failure in patients in sinus rhythm.

Authors:  William B Hood; Antonio L Dans; Gordon H Guyatt; Roman Jaeschke; John J V McMurray
Journal:  Cochrane Database Syst Rev       Date:  2014-04-28

Review 3.  Contemporary Controversies in Digoxin Use in Systolic Heart Failure.

Authors:  Chonyang L Albert; Forum Kamdar; Mazen Hanna
Journal:  Curr Heart Fail Rep       Date:  2016-10

Review 4.  Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data.

Authors:  Oliver J Ziff; Deirdre A Lane; Monica Samra; Michael Griffith; Paulus Kirchhof; Gregory Y H Lip; Richard P Steeds; Jonathan Townend; Dipak Kotecha
Journal:  BMJ       Date:  2015-08-30

5.  Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study.

Authors:  Maurizio Sessa; Annamaria Mascolo; Mikkel Porsborg Andersen; Giuseppe Rosano; Francesco Rossi; Annalisa Capuano; Christian Torp-Pedersen
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

6.  Association is not causation: treatment effects cannot be estimated from observational data in heart failure.

Authors:  Christopher J Rush; Ross T Campbell; Pardeep S Jhund; Mark C Petrie; John J V McMurray
Journal:  Eur Heart J       Date:  2018-10-01       Impact factor: 29.983

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.